Monrovia-based Xencor, a clinical-stage biopharmaceutical company, reported revenues for the second quarter ended June 30, 2015 of $1 million, compared to $0.8 million for the same period of 2014. Revenues for the six months ended June 30, 2015 were $2.5 million, compared to $3.0 million for the same period in 2014. http://goo.gl/mpQ61H
- Brad Haugaard
No comments:
Post a Comment